Panda Prateek Kumar, Elwadhi Aman, Gupta Diksha, Palayullakandi Achanya, Tomar Apurva, Singh Mayank, Vyas Antara, Kumar Deepak, Sharawat Indar Kumar
Department of Pediatrics, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.
Department of Digital Medicine, IMPUTE Inc., Tokyo, Japan.
J Neurosci Rural Pract. 2024 Apr-Jun;15(2):262-269. doi: 10.25259/JNRP_599_2023. Epub 2024 Feb 13.
IMPUTE Inc., a software firm dedicated to healthcare technology, has developed a mobile medical application known as IMPUTE ADT-1 for children with autism spectrum disorder (ASD) based on the principle of applied behavior analysis.
The primary objective of this trial was to compare the efficacy of add-on treatment with IMPUTE ADT-1 in children with ASD aged two to six years as compared to standard care alone for 12 weeks (in terms of change in Autism Diagnostic Observation Schedule [ADOS-2] scores). The secondary objective of the study was to assess the compliance with IMPUTE ADT-1 among participants and also to evaluate the feedback of parents regarding IMPUTE ADT-1 at the end of 12 weeks. The application provides personalized programs tailored to each user's needs, and the program evolves based on the user's progress. It also utilizes face tracking, eye tracking, and body tracking to gather behavior-related information for each child and apply it in reinforcement learning employing artificial intelligence-based algorithms.
Till the time of interim analysis, 37 and 33 children had completed 12-week follow-up in IMPUTE ADT-1 and control arm. At 12 weeks, as compared to baseline, change in social affect domain, repetitive ritualistic behavior domain, total ADOS-2 score, and ADOS-2 comparison score was better in the intervention group as compared to the control group ( < 0.001 for all). A total of 30 (81%), 28 (75%), and 29 (78%) caregivers in the IMPUTE ADT-1 group believed that the ADT-1 app improved their child's verbal skills, social skills, and reduced repetitive behavior, respectively.
IMPUTE ADT-1 mobile application has the efficacy to improve the severity of autism symptoms in children. Parents of these children also feel that the application is beneficial for improving the socialization and verbal communication of their children.
IMPUTE公司是一家专注于医疗技术的软件公司，基于应用行为分析原理，为自闭症谱系障碍（ASD）儿童开发了一款名为IMPUTE ADT - 1的移动医疗应用程序。
本试验的主要目的是比较在2至6岁的ASD儿童中，添加IMPUTE ADT - 1进行治疗与仅采用标准护理12周（根据自闭症诊断观察量表[ADOS - 2]评分变化）的疗效。该研究的次要目的是评估参与者对IMPUTE ADT - 1的依从性，并在12周结束时评估家长对IMPUTE ADT - 1的反馈。该应用程序提供根据每个用户需求量身定制的个性化程序，并且程序会根据用户的进展而演变。它还利用面部跟踪、眼睛跟踪和身体跟踪来收集每个孩子与行为相关的信息，并将其应用于基于人工智能算法的强化学习中。
到中期分析时，37名和33名儿童分别在IMPUTE ADT - 1组和对照组完成了12周的随访。在12周时，与基线相比，干预组在社会情感领域、重复仪式行为领域、ADOS - 2总分和ADOS - 2比较评分方面的变化优于对照组（所有P值均<0.001）。IMPUTE ADT - 1组中分别有30名（81%）、28名（75%）和29名（78%）的照料者认为ADT - 1应用程序提高了他们孩子的语言技能、社交技能并减少了重复行为。
IMPUTE ADT - 1移动应用程序有改善儿童自闭症症状严重程度的功效。这些儿童的家长也认为该应用程序有利于改善他们孩子的社交和语言沟通能力。
